Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19
Nature·
- DOI
- 10.1038/s41586-022-04630-3
- PMID
- 35314834
- PMCID
- PMC9783543
- OpenAlex
- W4221027163
- Study type
- Journal article
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The abstract highlights the PLA2G2D–PGD2/PTGDR pathway as a candidate therapeutic target for SARS-CoV-2, particularly in aged individuals, and positions asapiprant as one of the first interventions shown to specifically protect aged animals in this model.
Structured evidence summary
Research question
The paper investigates whether blocking the eicosanoid signalling pathway can protect aged or middle-aged animals from severe COVID-19, framed by the need for additional anti-SARS-CoV-2 therapies in aged populations where vaccine efficacy may be reduced.
Study design
Preclinical experimental study involving isolation of mouse-adapted SARS-CoV-2 variants and testing of a therapeutic intervention (a PTGDR antagonist) in genetically modified and aged mice, supplemented by ex vivo assays on human dendritic cells.
Population and setting
Middle-aged and aged laboratory mice infected with mouse-adapted SARS-CoV-2, together with human peripheral blood mononuclear cell-derived dendritic cells examined ex vivo; no human clinical trial or population-based setting is described.
Main findings
Adaptation of SARS-CoV-2 in mice produced spike changes (including positions 417, 484, 493, 498 and 501) also seen in human variants of concern. Expression of PLA2G2D and PTGDR and production of PGD2 increased with age and after SARS-CoV-2 infection in human dendritic cells. Middle-aged mice lacking PTGDR or PLA2G2D were protected from severe disease, and treatment with the PTGDR antagonist asapiprant protected aged mice from lethal infection.
Public-health relevance
The abstract highlights the PLA2G2D–PGD2/PTGDR pathway as a candidate therapeutic target for SARS-CoV-2, particularly in aged individuals, and positions asapiprant as one of the first interventions shown to specifically protect aged animals in this model.
Important limitations
The abstract does not state explicit limitations of the study. As a source-scope note, this summary is limited to the supplied single-article abstract and metadata and therefore cannot substitute for the original paper in evaluating methods, sample size, statistical robustness, or translational relevance to humans.
GIDS interpretation
Within GIDS terms, the article provides preclinical, mechanism-focused evidence relating to COVID-19 severity and candidate therapeutics in aged hosts. The abstract alone does not establish a live surveillance signal; claims about ongoing variant emergence or treatment uptake would require the original paper and external sources.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 12 auditable classifier relationships to diseases, places, topics, and study design.